Advertisement

Click here for more guidelines.

 
 




CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2006; 47:2429-2435, doi:10.1016/j.jacc.2006.01.074 (Published online 24 May 2006).
© 2006 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
j.jacc.2006.01.074v1
47/12/2429    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (21)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Granér, M.
Right arrow Articles by Taskinen, M.-R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Granér, M.
Right arrow Articles by Taskinen, M.-R.

CLINICAL RESEARCH: ATHEROSCLEROSIS

Association of Paraoxonase-1 Activity and Concentration With Angiographic Severity and Extent of Coronary Artery Disease

Marit Granér, MD*,*, Richard W. James, MD, PhD{dagger}, Juhani Kahri, MD, PhD*, Markku S. Nieminen, MD, PhD*, Mikko Syvänne, MD, PhD* and Marja-Riitta Taskinen, MD, PhD*

* Department of Internal Medicine, Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland
{dagger} Clinical Diabetes Unit, Division of Endocrinology and Diabetology, University Hospital, Geneva, Switzerland.

Manuscript received October 27, 2005; revised manuscript received January 7, 2006, accepted January 9, 2006.

* Reprint requests and correspondence: Dr. Marit Granér, Department of Internal Medicine, Division of Cardiology, Helsinki University Central Hospital, Haartmaninkatu 4, FIN-00290 HUCH, Finland. (Email: marit.graner{at}hus.fi).

OBJECTIVES: The goal of this study was to examine the association between paraoxonase-1 (PON1) activity and concentration and the severity and extent of coronary artery disease (CAD).

BACKGROUND: Paraoxonase-1, a high-density lipoprotein-associated enzyme, is proposed to have an antiatherogenic effect by protecting low-density lipoproteins against oxidation.

METHODS: We studied PON1 activity and concentration in 107 patients with known or suspected CAD referred for cardiac catheterization. Based on visual estimation of coronary angiograms, subjects were classified as having no or mild CAD (<50% stenosis) and significant CAD (≥50% stenosis). Quantitative coronary angiography (QCA) was used to estimate the indexes of severity, extent, and overall atheroma burden of CAD.

RESULTS: We found lower values of PON1 activity and concentration (p = 0.003 and p = 0.016, respectively) in the group with significant CAD as compared with the group with no or mild CAD. The PON1 activity was significantly inversely correlated with CAD severity (r = –0.364, p < 0.001), extent (r = –0.221, p = 0.022), and atheroma burden (r = –0.277, p = 0.004). Similarly, PON1 concentration correlated with CAD severity (r = –0.306, p = 0.001) and atheroma burden (r = –0.229, p = 0.017). In multiple regression analysis, gender and PON1 activity were significant determinants of the severity of CAD independently of age, hypertension, smoking, abnormal glucose regulation, and high-density lipoprotein cholesterol.

CONCLUSIONS: Our results indicate that PON1 activity and concentration are lower in subjects with significant CAD, and that there is a significant relationship between PON1 activity and concentration and CAD assessed by QCA.

Abbreviations and Acronyms
  apoA-I = apolipoprotein A-I
  apoA-II = apolipoprotein A-II
  apoB = apolipoprotein B
  CAD = coronary artery disease
  HDL = high-density lipoprotein
  LDL = low-density lipoprotein
  LpA-I = lipoprotein A-I
  PON1 = paraoxonase-1
  QCA = quantitative coronary angiography
  VLDL = very-low-density lipoprotein




This article has been cited by other articles:


Home page
PerfusionHome page
S. Kurban, I. Mehmetoglu, and E. Ege
Effect of preoperative atorvastatin therapy on paraoxonase activity and oxidative stress after coronary artery bypass grafting
Perfusion, July 1, 2009; 24(4): 271 - 276.
[Abstract] [PDF]


Home page
J Am Coll CardiolHome page
A. Hiukka, J. Westerbacka, E. S. Leinonen, H. Watanabe, O. Wiklund, L. M. Hulten, J. T. Salonen, T.-P. Tuomainen, H. Yki-Jarvinen, A. C. Keech, et al.
Long-Term Effects of Fenofibrate on Carotid Intima-Media Thickness and Augmentation Index in Subjects With Type 2 Diabetes Mellitus
J. Am. Coll. Cardiol., December 16, 2008; 52(25): 2190 - 2197.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
X. Moren, S. Deakin, M.-L. Liu, M.-R. Taskinen, and R. W. James
HDL subfraction distribution of paraoxonase-1 and its relevance to enzyme activity and resistance to oxidative stress
J. Lipid Res., June 1, 2008; 49(6): 1246 - 1253.
[Abstract] [Full Text] [PDF]


Home page
ANGIOLOGYHome page
M. V. Poulakou, K. I. Paraskevas, I. S. Vlachos, S.-A. P. Karabina, M. R. Wilson, D. C. Iliopoulos, S. I. Tsitsilonis, D. P. Mikhailidis, and D. N. Perrea
Effect of Statins on Serum Apolipoprotein J and Paraoxonase-1 Levels in Patients With Ischemic Heart Disease Undergoing Coronary Angiography
Angiology, May 1, 2008; 59(2): 137 - 144.
[Abstract] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement